J&J’s latest MedTech acquisition
Johnson & Johnson is focused on strengthening its medical device technologies business. On September 12, J&J’s medical device subsidiary announced the acquisition of EIT (Emerging Implant Technologies), a German developer of 3-D printed titanium interbody implants for spinal fusion surgery. The deal’s financial terms were not disclosed.
The acquisition advances J&J’s plans to expand its portfolio of spine solutions and strengthen its orthopedics business. In fiscal 2017, J&J reported a 6% decline in its spine business sales. The above diagram shows J&J’s spine business performance in 2017.
In the spinal interbody segment, J&J’s orthopedics business, DePuy Synthes, comprises the PROTI 360° family of titanium-integrated interbody implants with PEEK (polyetheretherketone) technology and Concorde Lift expandable interbody devices. The acquisition is a complementary fit for J&J’s interbody implant segment.
EIT’s advanced technology expected to bolster J&J’s implant business
EIT’s implants are developed using advanced cellular titanium with an open and interconnected porous structure that enables bones to grow into the implant. The company’s first fully 3D-printed adjustable interbody fusion cage was used for the first time in surgery earlier this year after the device was approved in Europe in February.
EIT uses additive manufacturing to build spinal implant technologies, which cuts device costs. Such lower-cost alternatives could help J&J gain a larger share of the spinal implant technology market.
Check out all the data we’ve added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data, as well as dividend information. Take a look!